Palabras clave
Diabetes mellitus tipo 2
Monitoreo continuo de glucosa
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Comparar la efectividad del monitoreo continuo de glucosa (MCG) con los tratamientos tradicionales para la diabetes mellitus tipo 2. Métodos: Se trata de una revisión integradora de la literatura realizada a través de las bases de datos PubMED, Biblioteca Virtual en Salud (BVS) y Periódico CAPES. los descriptores: “Adultos”, “Monitoreo Continuo de Glucosa”, “Diabetes Mellitus, Tipo 2” y “Resultado del Tratamiento” y obteniendo el truncamiento de búsqueda: (Monitoreo Continuo de Glucosa) AND (Diabetes Mellitus, Tipo 2) AND (Resultado del Tratamiento) AND (Adultos). Se encontraron 1.104 artículos, filtrados según criterios de inclusión (idiomas portugués, inglés y español; período de 2019 a 2024; artículos completos) y exclusión (artículos duplicados, resúmenes, fuera de alcance). Resultados: MCG permite monitorizar en tiempo real, reducir los episodios de hipoglucemia y mejorar el control glucémico, aunque el elevado coste supone un reto. Combinado con la telemedicina, MCG mejora la adherencia al tratamiento y la calidad de vida de los pacientes. Por el contrario, los métodos tradicionales enfrentan limitaciones como la inexactitud y la incomodidad de las punciones diarias, lo que afecta la adherencia y la eficacia del tratamiento. Conclusión: MCG es superior a los métodos tradicionales, ofreciendo mayor precisión y comodidad. Su adopción, con políticas de salud y capacitación adecuadas, puede transformar el manejo de la diabetes tipo 2, brindando una atención más efectiva y personalizada.
Referencias
ALICE Y, et al. Blood glucose monitoring in adults and children with diabetes: Update 2021. Canadian journal of diabetes, 2021; 45(7): 580–587.
ARADÓTTIR TB, et al. Feasibility of a new approach to initiate insulin in type 2 diabetes. Journal of diabetes science and technology, 2021; 15(2): 339–345.
BAKER M, et al. Practical implementation of remote continuous glucose monitoring in hospitalized patients with diabetes. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 2022; 79(6): 452–458.
CASTELLANA M, et al. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. BMJ open diabetes research & care, 2020; 8(1): 001092.
CHAO C, et al. Assessing non-adjunctive CGM safety at home and in new markets (ANSHIN). Endocrinology, diabetes & metabolism, 2023; 6(3): 414.
DIXON RF, et al. A virtual type 2 diabetes clinic using continuous glucose monitoring and endocrinology visits. Journal of diabetes science and technology, 2020; 14(5): 908–911.
EHRHARDT N, et al. Effectiveness of a culturally tailored diabetes education curriculum with real-time continuous glucose monitoring in a Latinx population with type 2 diabetes: the CUT-DM with CGM for Latinx randomised controlled trial study protocol. BMJ open, 2023; 13(12): 82005.
GERBER BS, et al. Mobile health intervention in patients with type 2 diabetes: A randomized clinical trial. JAMA network open, 2023; 6(9): 2333629.
HAAK T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: A multicenter, open-label randomized controlled trial. Diabetes therapy: research, treatment and education of diabetes and related disorders, 2017; 8(1): 55–73.
JANCEV M, et al. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetologia, 2024; 67(5): 798–810.
KARTER AJ, et al. Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA: the journal of the American Medical Association, 2021; 325(22): 2273–2284.
KAWAGUCHI Y, et al. Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring. Journal of diabetes investigation, 2024; 15(5): 598–607.
LIND N, et al. Peer support for adults with type 2 diabetes starting continuous glucose monitoring-An exploratory randomised controlled trial. Diabetic medicine: a journal of the British Diabetic Association, 2024; 41(6): 15321.
LIND N, et al. Real-time continuous glucose monitoring versus self-monitoring of blood glucose in adults with insulin-treated type 2 diabetes: a protocol for a randomised controlled single-centre trial. BMJ open, 2021; 11(1): 40648.
MATSUOKA A, et al. Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional study. Journal of diabetes investigation, 2020; 11(2): 417–425.
MUNAN M, et al. Acute and chronic effects of exercise on continuous glucose monitoring outcomes in type 2 diabetes: A meta-analysis. Frontiers in endocrinology, 2020; 11: 495.
OSER TK, et al. Personal continuous glucose monitoring use among adults with type 2 diabetes: Clinical efficacy and economic impacts. Current diabetes reports, 2021; 21(11).
RIBEIRO RT, et al. Impact of blinded retrospective continuous glucose monitoring on clinical decision making and glycemic control in persons with type 2 diabetes on insulin therapy. Nutrition, metabolism, and cardiovascular diseases: NMCD, 2021; 31(4): 1267–1275.
RIVERA-ÁVILA DA, et al. The effects of professional continuous glucose monitoring as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes. BMC endocrine disorders, 2021; 21(1): 79.
RUAN Y, et al. Association of body fat percentage with time in range generated by continuous glucose monitoring during continuous subcutaneous insulin infusion therapy in type 2 diabetes. Journal of diabetes research, 2021; 2021: 1–9.
SINGH LG, et al. Continuous glucose monitoring in general wards for prevention of hypoglycemia: Results from the glucose telemetry system pilot study. Journal of diabetes science and technology, 2020; 14(4): 783–790.
TAYLOR PJ, et al. Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: A narrative review. Journal of diabetes investigation, 2028; 9(4): 713–725.
YAJIMA T, et al., Comparison of interstitial fluid glucose levels obtained by continuous glucose monitoring and flash glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis. Journal of diabetes science and technology, 2020; 14(6): 1088–1094.
ZHENG M, et al. Comparing effects of continuous glucose monitoring systems (CGMs) and self-monitoring of blood glucose (SMBG) amongst adults with type 2 diabetes mellitus: a systematic review protocol. Systematic reviews, 2020; 9(1).